Controlling Cytokine Storm Is Vital in COVID-19

Lu Tang1,2, Zhinan Yin3,4, Yu Hu1,2* and Heng Mei1,2*

1 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, 3 Zhuhai Institute of Translational Medicine, Zhuhai People’s Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China, 4 The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, China

Corona virus disease 2019 (COVID-19) has caused a global outbreak and severely posed threat to people’s health and social stability. Mounting evidence suggests that immunopathological changes, including diminished lymphocytes and elevated cytokines, are important drivers of disease progression and death in coronavirus infections. Cytokine storm not only limits further spread of virus in the body but also induces secondary tissue damage through the secretion of large amounts of active mediators and inflammatory factors. It has been determined that cytokine storm is a major cause of deaths in COVID-19; therefore, in order to reverse the deterioration of severe and critically ill patients from this disease, the cytokine storm has become a key therapeutic target. Although specific mechanisms of the occurrences of cytokine storms in COVID-19 have not been fully illuminated, hyper-activated innate immune responses, and dysregulation of ACE2 (angiotensin converting enzyme 2) expression and its downstream pathways might provide possibilities. Tailored immunoregulatory therapies have been applied to counteract cytokine storms, such as inhibition of cytokines, corticosteroids, blood purification therapy, and mesenchymal stem cell therapy. This review will summarize advances in the research of cytokine storms induced by COVID-19, as well as potential intervention strategies to control cytokine storms.

Keywords: COVID-19, cytokine storm, ACE2, IL-6, immunoregulatory therapy

INTRODUCTION

Pathogenic human coronavirus infections, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), could cause fatal lower respiratory tract infections and extra-pulmonary manifestations (1–3). The Coronavirus Disease 2019 (COVID-19), first reported in Wuhan, China, has raised acute and grave global concern since December 2019 (4, 5). On March 11, 2020, the world health organization (WHO) officially declared a global pandemic status for COVID-19, which is a great threat to people’s health and social stability. In the early stages of COVID-19, severe acute respiratory infection symptoms occurred, and some patients rapidly developed acute respiratory distress syndrome (ARDS), acute respiratory failure, and other serious complications (6, 7). There is considerable evidence to show that immunopathological changes, including diminished lymphocytes and elevated cytokines, are important drivers of disease progression and death of COVID-19 patients, especially those who are critically ill (8). Early
detection and control of cytokine storms may effectively prevent disease progression and reduce the mortality rate. This review will summarize research progress on cytokine storms occurring in COVID-19 as well as potential intervention strategies.

Cytokine Storm and Cytokine Release Syndrome

The cytokine storm, previously reported in rheumatoid arthritis and graft-versus-host disease (GVHD), has been used to describe the overactive immune responses that can be triggered by a variety of factors, such as virus infection, autoimmune disease, and immunotherapies (8–10). Under the normal physiological state, the levels of pro-inflammatory cytokines and anti-inflammatory cytokines in the body are kept in relative balance, which can be broken by abnormal activation of a variety of immune cells (such as dendritic cells, macrophages, and lymphocytes) during viral infections. These abnormally activated immune cells could release large amounts of cytokines, among which the pro-inflammatory cytokines could promote more immune cells in a positive feedback loop. The formation of cytokine storm leads to “suicide attack” that not only contributes the elimination of pathogenic microorganisms but also causes tissue toxicities affecting a wide variety of organs (Table 1) (9). The cytokine release syndrome (CRS), a kind of systemic inflammation syndrome caused by cytokine storm, was previously observed in patients infected with SARS-CoV and MERS-CoV, as well as in leukemia patients receiving engineered T cell therapy (8, 9, 11, 12). Mild cases are characterized by fever, fatigue, headache, rash, arthralgia, and myalgia. Patients with more severe symptoms usually present with high fever, headache, fatigue, diffuse intravascular coagulation (DIC), shock, multiple organ failure (MOF), or even death (9, 11). Common laboratory abnormalities include cytopenia, elevated creatinine and liver enzymes, high levels of C-reactive protein (CRP), and deranged coagulation parameters (9, 11). Lee et al. reported a modified grading system for the severity of CRS regardless of the inciting agent, which defined mild, moderate, severe, life-threatening symptoms, and even death. This grading system is also used to guide clinical decisions in CRS (11). Vigilant supportive care is recommended for every grade; immunosuppression should be used in all patients with grade 3 or 4 CRS and instituted earlier in patients with extensive comorbidities or the elderly (11).

**Cytokine Storm Induced in Viral Infection**

The virus can promote the activation of immune cells (such as T cells, B cells, macrophages, dendritic cells, neutrophils, monocytes) and resident tissue cells, resulting in the production of large amounts of inflammatory cytokines (13, 14). During the flu virus infection, innate immune responses get started through the cascade amplification reactions of interferon stimulated gene expression, and type I interferon (IFN) is mainly produced by monocytes, macrophages and dendritic cells (15). Serum levels of interleukin 8 (IL-8), IP-10 (interferon-induced protein 10), MCP-1 (monocyte chemoattractant protein-1), MIP-1 (macrophage inflammatory protein-1), MIG (monokine induced by IFN-γ) and CXCL-9 (CXC chemokine ligand-9) were abnormally elevated in H5N1 influenza virus infection, while IL-8, IL-9, IL-17, IL-6, IL-15, TNF-α (tumor necrosis factor-α), IL-10 were increased in H1N1 influenza virus infection (16–18). Earlier researches demonstrated that serum levels of proinflammatory factors IFN-γ, IL1β, IL-6, IL-12, IL-18, IP-10, MCP-1, and CCL2 (CC chemokine ligand-2), CXCL-10 and IL-8 are positively correlated with lung inflammation and extensive lung tissue injury in SARS patients (19–21). Whereas, the levels of serum pro-inflammatory cytokines IL-6, IFN-γ, TNF-α, IL-15, IL-17, and chemokines IL-8, CXCL-10, and CCL5 were significantly increased in severe MERS patients (22, 23). Among numerous molecules that increase in virally-mediated cytokine storms, IL-6, IFN-γ, IL-1β, IL-8, IL-10, and TNF-α are of crucial importance (9, 24, 25). The occurrence of cytokine storm has been reported to be one of the main causes of death in patients with SARS-CoV, MERS-CoV, and influenza virus infections (8, 26). Similarly, cytokine storm is also a common feature of severe cases in COVID-19, and elevated levels of serum IL-6 and CRP correlate with respiratory failure, ARDS, MOF and adverse clinical outcomes (27, 28).

**Pathophysiology of Cytokine Storm**

Both damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) are produced upon viral infection, which can activate antiviral responses in neighboring cells as well as recruit innate and adaptive immune cells, such as macrophages, natural killer (NK) cells, and gamma-delta T (γδ T) cells (Figure 1) (24, 29–33). Downstream production of interferons promotes intracellular viral

![Table 1](https://example.com/table1.png)

**Table 1** Clinical signs and laboratory findings about cytokine storms.

| Organ          | Clinical signs and laboratory findings                                                                 |
|----------------|----------------------------------------------------------------------------------------------------------|
| Constitutional | Fever, rigors, headache, malaise, fatigue, anorexia, myalgias, nausea, vomiting                           |
| Pulmonary      | Tachypnea, hypoxemia                                                                                    |
| Hematologic    | Anemia, thrombocytopenia, neutropenia, febrile neutropenia, lymphopenia, B-cell aplasia, hypoferremia, bleeding, elevated D-dimer, prolonged prothrombin time, prolonged activated partial prothrombin time, disseminated intravascular coagulation |
| Gastrointestinal | Nausea, diarrhea, emesis                                                                               |
| Cardiovascular | Tachycardia, widened pulse pressure, hypotension, arrhythmias, QT prolongation, increased cardiac output (early), potentially diminished cardiac output (late) |
| Renal          | Acute kidney injury, hyponatremia, hypokalemia, hypophosphatemia, tumor lysis syndrome, azotemia          |
| Hepatic        | Transaminases, hyperbilirubinemia                                                                       |
| Neurologic     | Headache, mental status changes, confusion, delirium, word finding difficulty or frank aphasia, hallucinations, tremor, dysetria, altered gait, seizures |
| Skin           | Rash, edema                                                                                            |
defenses in neighboring epithelial cells which may limit viral dissemination, while the release of IL-6 and IL-1β from other immune cells promotes recruitment of neutrophils and T cells (29). Subsequently, the activation of T cells or lysis of immune cells induces secretion of IFN-γ and TNF-α, leading to the activation of immune cells and endothelial cells with further release of pro-inflammatory cytokines in a positive feedback loop manner (9). Although these inflammatory cytokines promote T follicular helper (Tfh) cell differentiation, B cell germinal center formation and antibody production, as well as Th1 (T helper 1) cell differentiation and cytotoxic CD8+ T cell generation to help viral removal, tissue damage caused by them cannot be ignored (34, 35). Activated neutrophils release leukotrienes and reactive oxygen species (ROS) that induce local pneumocyte and endothelial injury, directly leading to acute lung injury (29). Inflammatory mediators promote neutrophil release of nuclear deoxyribonucleic acid (DNA) to form neutrophil extracellular traps (NETs) which can snare pathogens as well as contribute to thrombi formation (33). This process, termed immunothrombosis, can also amplify the production of cytokines and is exemplified by links of thrombin with inflammasome activation and production of IL-1 (36). As vascular endothelial cells would be exposed to circulating cytokines and other immune mediators, coagulation disorders (such as capillary leak syndrome, thrombus formation, and even DIC) can also be caused by endothelial cell dysfunction in cytokine storms, indicating the crosstalk between hemostasis and cytokines (24, 33). High levels of circulating inflammatory cytokines can cause cell death as well as tissue damage, whereas their promotion of macrophages activation can lead to erythro-phagocytosis and anemia (24, 33). The successive occurrences of acute lung injury, abnormal alterations in vascular hemostasis, and cytokine-mediated tissue damage can eventually result in MOF (24, 33, 37).

As discussed above, cytokine storm not only limits further spread of virus but also induces secondary tissue damage through the secretion of a large number of active mediators and inflammatory factors. Inflammatory mediators promote neutrophil release of nuclear deoxyribonucleic acid (DNA) to form neutrophil extracellular traps (NETs) which can snare pathogens as well as contribute to thrombi formation (33). This process, termed immunothrombosis, can also amplify the production of cytokines and is exemplified by links of thrombin with inflammasome activation and production of IL-1 (36). As vascular endothelial cells would be exposed to circulating cytokines and other immune mediators, coagulation disorders (such as capillary leak syndrome, thrombus formation, and even DIC) can also be caused by endothelial cell dysfunction in cytokine storms, indicating the crosstalk between hemostasis and cytokines (24, 33). High levels of circulating inflammatory cytokines can cause cell death as well as tissue damage, whereas their promotion of macrophages activation can lead to erythro-phagocytosis and anemia (24, 33). The successive occurrences of acute lung injury, abnormal alterations in vascular hemostasis, and cytokine-mediated tissue damage can eventually result in MOF (24, 33, 37).

As discussed above, cytokine storm not only limits further spread of virus but also induces secondary tissue damage through the secretion of a large number of active mediators and inflammatory factors (Figure 1) (24, 29–33, 35, 38, 39). Thus, it can be seen that inhibition of this self-amplifying inflammatory cascade may not only control tissue damage, but also impair viral clearance. Unlike that in viral infection, the occurrence of cytokine storm in CAR-T therapy is secondary to T cell-mediated killing of tumor cells, and inhibition of this self-amplifying inflammatory cascade has no influence on therapeutic efficacy (9, 29). Nevertheless, it has been proved that antiviral immune responses and tissue toxicity could be at least partially uncoupled; therefore, inhibition of select arms of innate immune responses could limit tissue toxicity while not greatly suppressing ongoing antiviral immunity (29).
Clinical, Pathological, and Serological Manifestations in COVID-19

The incubation period of COVID-19 patients ranged from 1 to 14 days, and mostly from 3 to 7 days (8, 40). Common symptoms at onset of illness were fever, dry cough, myalgia, fatigue, dyspnea, and anorexia; however, a few patients presented initially with atypical symptoms, such as diarrhea and nausea (6, 40). Most patients had good results with treatment, while the elderly patients and those with chronic diseases usually had poor prognoses. Although most patients with COVID-19 had mild and moderate symptoms, severe and critically ill patients progressed rapidly to acute respiratory failure, ARDS, metabolic acidosis, coagulopathy, septic shock, and MOF (7, 40–42). The autopsy report in the journal The Lancet Respiratory Medicine showed typical ARDS-like lung injury with lymphocyte infiltration, liver injury with moderate micro-vascular steatosis, mild lobular and portal activity (43). COVID-19 patients usually revealed significantly reduced lymphocyte counts and increased inflammatory factors, especially those with severe illnesses (6, 40, 44). Wang et al. reported that the neutrophil count and D-dimer continued to increase in non-survivors, whereas lymphocyte counts continued to decrease until death occurred (40). Neutrophilia may be related to cytokine storms induced by virus invasion, and coagulation activation may be related to sustained inflammatory responses (40).

Cytokine Storm Is a Key Determiner in the Fate of COVID-19

Huang et al. observed that patients in intensive care unit (ICU) showed higher levels of plasma inflammatory cytokines IL-2, IL-7, IL-10, G-CSF (granulocyte colony-stimulating factor), IFN-γ and MCP and TNF-α than non-ICU patients (6), indicating the positive correlation between the cytokine storm and the severity of illness. These cytokines suggested not only Th1 responses but also Th2 responses in COVID-19, which differed from SARS-CoV infections (6). After being infected with the SARS-CoV-2, CD4+ T cells were activated and differentiated into Th1 cells to secrete pro-inflammatory cytokines, such as IL-6, IFN-γ, and GM-CSF (granulocyte-macrophage colony stimulating factor) (6, 45). GM-CSF could activate mononuclear cells to promote further release of IL-6 and other pro-inflammatory cytokines, leading to the generation of cytokine storms (45). Therefore, IL-6 and GM-CSF released by T lymphocytes and mononuclear cells may be the key link of cytokine storm in COVID-19 (45). Moreover, the activation of monocytes may suggest that the cytokine storm in COVID-19 is closely related to the destruction of the balance between innate and adaptive immunity.

Recent studies also showed that the level of IL-6 in severe cases was significantly higher than that in mild and moderate cases, but the levels of CD4+ T cells, CD8+ T cells and NK cells were decreased, indicating the immunosuppression in severe COVID-19 patients (44). Although peripheral CD4+ T cells and CD8+ T cells were significantly reduced, the number of Th17 cells increased and CD8+ T cells were highly cytotoxic, which further suggested that cytokine storms may aggravate tissue damage (43). Meanwhile, T lymphocyte cells were excessively activated during the cytokine storm in COVID-19 patients, which may be accompanied by severe immune dysfunctions (43). The cytokine storm can directly damage the pulmonary capillary mucosa, promote alveolar edema, and further induce the diffusion of inflammatory cytokines, thus resulting in the damage of alveolar structure and pulmonary ventilation dysfunction (25, 46). In addition, the cytokine storm is associated with the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome (MODS) (37). Therefore, the cytokine storm may be an important factor that affects the fate of patients with COVID-19 pneumonia.

POSSIBLE MECHANISMS OF CYTOKINE STORM IN COVID-19

Hyperactivated Innate Immune Responses

During the process of antiviral immune responses, innate and adaptive immune responses interact with each other and cooperate closely to produce immune protection (47). There is a time limit for adaptive immune responses, which usually gets initiated 4 to 7 days after infection. Unlike adaptive immune responses, innate immune responses occur immediately after infection and are fully involved in virus clearance. However, the innate immunity is relatively weak in virus clearance, and adaptive immunity is the key factor in complete elimination of the virus (47). If the body does not generate effective adaptive antiviral responses in time to clear the virus, the innate immune responses will be strengthened, which cannot eliminate the virus effectively and even lead to systematic inflammation responses with uncontrolled release of inflammatory cytokines (48, 49). The latest studies have shown that the average age of severe and critically ill patients is higher than that of mild cases (66-years old vs. 51-years old), and severe cases are more likely to have other chronic diseases (72.2% vs. 37.3%) (40, 50). As for the elderly patients and those with chronic diseases, it takes a longer period of time to generate effective adaptive immune responses due to the deterioration of immune functions. These patients only rely on strengthening the innate antiviral immune responses in the early stages of infection, leading to a higher risk of cytokine storms, earlier onset of severe illness, and a higher mortality rate. Although the kinetics of the responses to SARS-CoV-2 fit with models of the induction of conventional antiviral immunity, it is still unclear whether innate hyperactivity is due to ongoing viral replication or immune dysregulation (33). Pyroptosis is a highly inflammatory and caspase-1-dependent form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is a part of the antimicrobial responses, which may also play a role in COVID-19 pathogenesis (51, 52). Rapid viral replication that causes increased pyroptosis may lead to a massive release of inflammatory mediators (51). Taken together, viral escape to avoid anti-viral immunity, together with genetic or acquired defects in host defense, may impair viral clearance, resulting in inappropriate immune activation and consequently causing cytokine storms (52). In a word, the exaggerated activation of innate immunity may be an important factor in the formation of cytokine storms in COVID-19 (29).
Dysregulation of ACE2 and Its Downstream Pathway

Angiotensin converting enzyme 2 (ACE2) primarily catalyzes the breakdown of angiotensin II (AngII) to maintain the homeostasis of renin-angiotensin-aldosterone system (RAAS) as a pivotal counter-regulator, which is crucial for the physiology and pathology of most human organs (53, 54). Significant to COVID-19, ACE2 has been established as the functional host receptor for SARS-CoV-2, and many factors have proved to be associated with both altered ACE2 expression and disease severity and progression, including age, sex, ethnicity, medication, and several co-morbidities (such as cardiovascular disease, metabolic syndrome, and lung cancer) (53–57). Recent studies have also revealed potential roles of ACE2 in regulating immune responses rather than merely being a viral-binding receptor in COVID-19 (53–55, 58-61). Chen’s team found the expression axis “mir-125b-5p–ACE2–IL-6” existed in lung adenocarcinoma, in which mir-125b-5p inhibited the expression of IL-6 through promoting the up-regulation of ACE2 (58). Once bound by SARS-CoV-2, the ACE2 expression (including mRNA level and enzyme activity) on the surface of host cells were significantly decreased, and then IL-6 in the toll-like receptor signaling pathway might influence the immune system as the downstream effector (53, 54, 58). Therefore, the dysregulation of ACE2 induced by SARS-CoV-2 infection may further cause cytokine storms and pneumonia, and targeting to the upstream regulator mir-125b-5p may provide a new way for the control of COVID-19 (58, 60). More interestingly, the spike protein of SARS-CoV has been previously demonstrated to downregulate ACE2 expression, thus resulting in over-production of AngII (the downstream of ACE2) by the related enzyme ACE (62, 63). Similarly, it could be hypothesized that SARS-CoV-2 may downregulate ACE2 receptors and thereby leading to an over-production of AngII, which may be another possible explanation of cytokine storm in COVID-19 (59, 61). ACE2 molecules on the cell surface are occupied by SARS-CoV-2, and then AngII increases due to a reduction of ACE2-mediated degradation (59, 61). SARS-CoV-2 itself activates nuclear factor kappa B (NF-kB) via pattern recognition receptors (PRRs), and the accumulated AngII in turn induces the activation of the IL-6 amplifier through enhanced activation of NF-kB pathway and IL-6-STAT3 (signal transducers and activators of transcription family 3) axis (61). IL-6 is a key factor in this positive feedback loop, ultimately leading to the release of cytokines out of control (64). More importantly, IL-6 is a major functional marker of cellular senescence, and the age-dependent enhancement of the IL-6 amplifier may correspond to the age-dependent increase of COVID-19 mortality (61, 64).

CONTROLLING CYTOKINE STORM IS VITAL IN COVID-19

Lessons should be learned from the outbreak of SARS-CoV and MERS-CoV to accumulate valuable experience and insights on how to effectively treat COVID-19 pneumonia patients. There are three progressive stages upon SARS-CoV-2 infection: early infection, pulmonary phase, and hyper-inflammation phase (65). Targeted treatments are urgently needed to prevent the occurrence of cytokine storms, and the early infection stage with no or mild symptoms is the key period for active treatment to control further deterioration (65). Antiviral drugs that inhibit virus transmission and destroy virus replication can reduce direct cell damage caused by COVID-19, and appropriate combinations with immunoregulatory therapies that inhibit hyper-activated inflammatory responses can resist cytokine storms triggered by the virus (Figure 1 and Table 2) (72, 73). Multiple clinical trials have been initiated to investigate potential interventions to control cytokine storms in patients with COVID-19, mainly including direct inhibition of cytokines and immunomodulatory therapies (Figure 1 and Table 2).

Inhibition of Cytokines

Blocking of IL-6/IL-6R

One meta-analysis of mean IL-6 concentrations demonstrated 2.9-fold higher levels in patients with complicated COVID-19 compared with those with non-complicated disease (74), and another meta-analysis also reported the relation between IL-6 levels and severe condition (75), indicating that IL-6 was a good indicator of poor prognosis in COVID-19 (74). At present, blockers of IL-6/IL-6R have been preliminarily applied in a series of ongoing clinical trials of COVID-19 and further multi-center clinical trials are being carried out (Table 2). Tocilizumab (a kind of IL-6 receptor blocker, IL-6R), first approved for rheumatic conditions, can effectively reverse iatrogenic cytokine storms which are caused by CAR-T therapy in patients with hematological malignancies (11, 76). One clinical trial from China (ChiCTR2000029765) reported that tocilizumab made rapid improvements in fever control and respiratory functions in 21 severe patients with COVID-19, and all participants including two seriously ill patients recovered and were discharged from the hospital (77, 78). Roumier et al. reported their experience regarding tocilizumab in 30 COVID-19 patients, suggesting that tocilizumab significantly reduced mechanical ventilation requirements (odd ratio, OR=0.42) and risk of subsequent ICU admissions (OR=0.17) (79). Toniati’s group published a single center study of 100 COVID-19 patients in Italy and also demonstrated that the response to tocilizumab was rapid, sustained, and associated with significant clinical improvements (80). A systematic review and meta-analysis of observational studies found decreased mortality in COVID-19 patients treated with tocilizumab (81). In addition, IL-6 blockade with tocilizumab does not impair the viral specific antibody responses despite of a delayed viral clearance driven by a higher initial viral load, indicating the safety of tocilizumab in patients with COVID-19 (82). Sarilumab is another kind of IL-6R blocker that is being investigated in SARS-CoV-2 infection (83, 84), which may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 (85). Although not yet approved by Food and Drug Administration (FDA), clazakizumab (a monoclonal antibody
| Trial identifier | Participants | Trial design | Therapy | Mechanism | Adverse effects |
|-----------------|--------------|-------------|---------|-----------|-----------------|
| ChiCTR2000029765 | Adult (18–85 years), moderate/severe/critically ill patients | A multicenter, randomized controlled trial | Tocilizumab vs. Standard medical care | IL-6 receptor blocker | Infections; skin rash; anemia; neutropenia; lymphopenia; liver enzyme elevations etc. |
| ChiCTR2000030796 | Diagnosed cases | A retrospective study | Tocilizumab | | |
| ChiCTR2000030894 | Adult (18 Years to 65 Years), moderate/severe patients | A multicenter, randomized, controlled trial | Tocilizumab combined with Favipiravir vs. Standard medical care | | |
| NCT04332913 | Adult, severe/critically ill patients | A prospective, observational study | Tocilizumab | | |
| NCT04322773 | Adult, severe/critically ill patients | An open-Label, multicenter sequential, cluster randomized trial | Tocilizumab vs. Sarilumab vs. Standard medical care | | |
| NCT04317092 | Adult, severe/critically ill patients | A multicenter, single-arm, open-label, phase 2 study | Tocilizumab | | |
| NCT04320615 | Adult, severe/critically ill patients | A randomized, double-blind, placebo-controlled, multicenter, phase 3 trial | Tocilizumab vs. Placebo | | |
| NCT04306705 | Adult, severe/critically ill patients | A retrospective study | Tocilizumab vs. Standard medical care vs. Continuous renal replacement therapy | | |
| NCT04315480 | Adult, severe/critically ill patients | A phase 2 Simon’s optimal two-stages trial | Tocilizumab | | |
| NCT04335071 | Adult, severe/critically ill patients | A multicenter, double-blind, randomized controlled phase II trial | Tocilizumab vs. Placebo | | |
| NCT04324073 | Adult, moderate/severe/critically ill patients | A multiple, open-label, randomized controlled trial | Sarilumab vs. Standard medical care | | |
| NCT04315298 | Adult, severely/critically ill patients | An adaptive phase 2/3, randomized, double-blind, placebo-controlled Study | Sarilumab vs. Placebo | | |
| NCT04327388 | Adult, severely/critically ill patients | An adaptive phase 3, randomized, double-blind, placebo-controlled trial | Sarilumab vs. Placebo | | |
| NCT04341870 | Adult (18–80 years), moderate/severe/critically ill patients | A multicenter open-label 1:1 randomized controlled trial | Sarilumab vs. Azithromycin vs. Hydroxychloroquine | | |
| NCT04348500 | Adult patients with pulmonary involvement who have not yet required mechanical ventilation and/or ECMO | A single center, randomized, double-blind, placebo-controlled, exploratory phase II study | Clazakizumab vs. Placebo | IL-6 monoclonal antibody | |
| Trial identifier | Participants | Trial design | Therapy | Mechanism | Adverse effects |
|------------------|--------------|--------------|---------|-----------|-----------------|
| NCT04322188 (66) | Adult, severe/critically ill patients | A single-center observational cohort study | Siltuximab vs. Standard medical care | Siltuximab vs. methylprednisolone | IL-1 receptor antagonist blocking IL-1α and IL-1β |
| NCT04329650 | Adult, severe/critically ill patients | A phase 2, randomized, open-label study | Anakinra vs. Standard medical care | Anakinra vs. Tocilizumab vs. Siltuximab vs. Usual Care | Infections; skin rash; anemia; neutropenia; lymphopenia; liver enzyme elevations etc. |
| NCT04318366 (67) | Adult, moderate to severe patients | A retrospective cohort study | Anakinra vs. Standard medical care | | |
| NCT04330638 | Adult, severe/critically ill patients | A prospective, randomized, factorial design, interventional Study | Anakinra vs. Tocilizumab vs. Siltuximab vs. Usual Care | | |
| NCT04341584 | Adult, severe/critically ill patients | A multiple randomized controlled trial | Adalimumab vs. Standard medical care | | IL-1β monoclonal antibody |
| NCT04339712 | Adult, severely ill patients | A non-randomized, open-label trial | Anakinra vs. Tocilizumab | | |
| NCT04365153 (68) | Adult, severely ill patients with cardiac injury | A double-blind, randomized controlled trial | Canakinumab vs. Placebo | | |
| NCT04348448 (69) | Adult (18–100 years), severely ill patients | A prospective, observational study | Canakinumab | | |
| ChiCTR2000030089 | Adult, severely ill patients | A randomized, open-label, controlled trial | Adalimumab vs. Standard medical care | | |
| NCT04324021 (70) | Adult (30–79 years), severely ill patients | An open label, controlled, parallel group, 3-arm, multicenter study | Emapalumab vs. Anakinra vs. Standard medical care | | |
| NCT04358614 | Adult, moderate patients | A phase 2/3, open label, clinical trial | Baricitinib vs. Standard medical care | | |
| NCT04321993 | Adult, severely ill patients | An open label, non-randomized, parallel group study | Baricitinib vs. Standard medical care | | |
| NCT04320277 | Adult (18–85 years), mild/moderate patients | An open label, non-randomized, crossover assignment study | Baricitinib vs. Standard medical care | | |
| NCT04346147 | Adult, non-severe patients | A prospective, phase II, randomized, open-label, parallel group study | Baricitinib vs. Hydroxychloroquine vs. Lopinavir/ritonavir vs. Imatinib | | |
| NCT04340232 | Adult (18–89 years), without invasive oxygen supplementation | A single arm, open label study | Baricitinib | | |
| NCT04321993 | Adult, severely ill patients | A parallel, open-label, non-randomized intervention trial | Baricitinib vs. Standard medical care | | |
| NCT04348695 | Adult, severe patients | A randomized, open label, phase II trial | Ruxolitinib plus simvastatin vs. Standard medical care | | |
| NCT04331665 | 12 Years and older, require supplemental oxygen | A single arm open label clinical study | Ruxolitinib | | |

(Continued)
| Trial identifier | Participants | Trial design | Therapy | Mechanism | Adverse effects |
|------------------|--------------|-------------|---------|-----------|----------------|
| NCT04337359     | 6–90 years, severe/critically ill patients | A single arm open-label, intermediate-size population | Ruxolitinib |         |                |
| NCT04338958     | Adult, severe/critically ill patients | A single arm, non-randomized open phase II trial | Ruxolitinib |         |                |
| NCT04348071     | Adult (18–89 years), requires supportive care | An adaptive phase 2/3 clinical trial | Ruxolitinib vs. Standard medical care |         |                |
| NCT04332042     | Adult (18–65 years), hospital admission from less than 24 h | A prospective, single cohort, open study | Tofacitinib | JAK1/JAK3 inhibitor |                |
| NCT04322682     | 40 Years and older, possess at least one high-risk criteria | A randomized, double-blind, placebo-controlled, multi-center study | Colchicine vs. Placebo oral tablet | Inhibition of pyrin and NLRP3 inflammasome activation | Diarrhea; pancytopenia nausea; abdominal pain etc. |
| NCT04325565     | Adult (18–100 years), severe patients | A prospective, phase II randomized, open-label, Parallel Group Study | Colchicine vs. Standard of care |         |                |
| NCT04328480     | Adult, severe/critically ill patients | A simple pragmatic randomized open controlled trial | Colchicine vs. Local standard of care |         |                |
| NCT04326790 (1/1) | Adult, severe/critically ill patients | An open label, randomized, parallel group study | Colchicine vs. Standard of care |         |                |
| NCT04350320     | Adult, admitted in the hospital in the previous 48 hours, with clinical status 3, 4, or 5 of WHO classification. | A phase III, prospective, pragmatic, randomized, controlled and open-label trial | Colchicine vs. Standard of care |         |                |
| ChiCTR2000029386 | Adult, severe/critically ill patients | A prospective, phase II, randomized, open-label, Parallel Group Study | Methylprednisolone vs. Standard of care | Promote the inhibition of HAT and recruitment of HDAC2 activity to downregulate inflammatory genes | Serious Infections: pneumonia, herpes zoster, urinary tract infection; fever; allergy; thrombosis; abnormal blood glucose and pressure; arrhythmia etc. |
| ChiCTR2000029666 | Adult, severe/critically ill patients | A randomized, open-label study | Methylprednisolone vs. Standard of care |         |                |
| NCT04263402     | Adult, severely/critically ill patients | An open, prospective/retrospective, randomized controlled Cohort Study | Methylprednisolone vs. Standard of care |         |                |
| ChiCTR2000030503 | Adult, severely/critically ill patients in ICU | A prospective cohort stud | Blood purification therapy | Remove elevated inflammatory mediators and cytokines | Allergies; fever, thrombosis; hypotension; thrombocytosis; bleeding; air embolism etc. |
| ChiCTR2000029666 | Adult, critically ill patients | An open, randomized controlled trial | Menstrual Blood-derived Stem Cells | Inhibit abnormal activation of T cells and macrophages and induce their differentiation into regulatory T cells and anti-inflammatory macrophages; obstruct the secretion of pro-inflammatory cytokines. | Allergies; fever, arrhythmia etc. |
| ChiCTR2000031139 | Adult (18–80 years), severely/critically ill patients | An open label, single arm study | Embryonic MSCs |         |                |
| ChiCTR200003088 | Adult (18–80 years), severely/critically ill patients | An open label, randomized, parallel group study | Wharton’s Jelly MSCs |         |                |
| NCT04269525     | An open label, single arm study | Umbilical cord-derived MSCs |         |         |                |

(Continued)
against human IL-6) may be helpful in inhibiting the cytokine storms, and related clinical trials are underway worldwide (86). It is also reported that patients with rapidly progressing COVID-19 respiratory failure requiring ventilatory support may benefit from treatment with siltuximab (IL-6 monoclonal antibody) because of reduced mortality and cytokine-driven hyperinflammation (NCT04322188) (66).

### Blocking of IL-1 Family

There are three important cytokines of IL-1 family in cytokine storms: IL-1β, IL-18, and IL-33, among which the block of IL-1β to counteract the cytokine storms is of great concern (9, 29). Anakinra, a kind of IL-1 receptor antagonist that blocks activity of both IL-1α and IL-1β, has been approved by the FDA and the EDA (European Drug Administration) for the treatment of rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, and familial Mediterranean fever (67, 87, 88).

Anakinra can also be used in the treatment of cytokine storms caused by infection, significantly improving the survival rate of severe sepsis (89). Compared with other cytokine blockers, anakinra has shorter half-life; thus, it is safer and more suitable for severe and critically ill patients. A retrospective cohort study (NCT04324021) reported that high doses of intravenous anakinra inhibit systemic inflammation and were associated with progressive improvement in respiratory function in severe patients with COVID-19 (70). Other clinical trials are also under way to evaluate the use of anakinra in COVID-19 (NCT04330638, NCT04341584, NCT04339712 etc.). Canakinunab, a monoclonal antibody selectively targeting IL-1β, is also being investigated in the treatment for COVID-19. It was proved that canakinunab was safe, well tolerated, and associated with a rapid reduction in the systemic inflammatory response and an improvement in cardiac and respiratory function (68, 69). Nevertheless, strengthened evidence for the application of anakinra and canakinunab in COVID-19 are required in further random controlled trials.

### Other Blockers

There is no clinical evidence nor any registered clinical trials assessing the possibility of IL-18 blockers and IL-33 blockers in COVID-19. TNF-α and IFN-γ are also key inflammatory cytokines and attractive targets in the control of cytokine storms (6, 90, 91), and clinical trials are ongoing to test these blockers in COVID-19 (ChiCTR2000030089, NCT04324021) (70, 92). JAK/STAT (Janus kinase/signal transducers and activators of transcription) signal transduction pathway, a common downstream signaling pathway of various cytokines, can block multiple targeted cytokines at the same time if inhibited (93, 94). However, its possible side effects cannot be ignored, such as increased risk for pulmonary embolism (PE), liver enzyme elevations, hematological abnormalities and suppression of antiviral immunity (94–96). Several representative JAK inhibitors, such as tofacitinib, baricitinib, and ruxolitinib, are currently being investigated to determine whether they can be applied to the treatment of COVID-19 (NCT04332042, NCT04348695, NCT04321993, NCT04348695, etc.) (94). Baricitinib and ruxolitinib are selective inhibitors of JAK1/JAK2 which is responsible for multiple cellular signals including the proinflammatory IL-6 and works as immunomodulator decreasing the cytotoxic T lymphocytes and increasing the regulatory T cells (97, 98). A phase 2/3 clinical trial (NCT04358614) showed that all clinical characteristics and respiratory function parameters significantly improved in the baricitinib-treated group compared to the baseline, and no serious infections, cardiovascular and hematologic adverse effects occurred after treatment (29).

Although tofacitinib is a selective inhibitor of JAK1/JAK3, it is suggested that for patients not on tofacitinib that this be initiated, but rather for those already on it that it can potentially be continued during a pandemic (99). Colchicine can inhibit the inflammasome activation of pyrin and NLRP3 (NLR Family Pyrin Domain Containing 3), and are also currently under way to be evaluated in the treatment of COVID-19 (71, 100, 101). A

| Trial identifier | Participants | Trial design | Therapy | Mechanism | Adverse effects |
|------------------|--------------|-------------|---------|-----------|----------------|
| NCT04252118     | Adult (18–70 years), severe/critically ill patients | An open label, non-randomized, parallel group study | MSCs vs. Standard of care | Improved respiratory parameters and cardiac function | |
| NCT04288102     | Adult (18–75 years), severe/critically ill patients | A phase II, multicenter, randomized, double-blind, placebo-controlled trial | MSCs vs. Standard of care | Improved respiratory parameters and cardiac function | |
| NCT04276987     | Adult (18–75 years), severe/critically ill patients | An open label, single arm, pilot clinical study | Allogenic adipose MSCs | Improved respiratory parameters and cardiac function | |
| NCT04273646     | Adult (18–65 years), severe/critically ill patients | Umbilical cord-derived MSCs vs. Standard of care | Improved respiratory parameters and cardiac function | |

Table 2 | Continued
single-center cohort study showed that patients treated with colchicine had a better survival rate as compared with standard care at 21 days of follow-up, and the adverse effects were similar for two groups, which may support the rationale of use of colchicine for the treatment of COVID-19 (100). Another randomized clinical trial of 105 COVID-19 patients also suggested that low-dose of colchicine combined anti-inflammatory action with a favorable safety profile (71). Moreover, it is also recommended as a therapeutic option in patients who have contraindications to other drugs or in the context of shortage/unavailability of anti-viral drugs (such as in underdeveloped countries) due to high availability (101).

Corticosteroids
Corticosteroids, a type of steroid hormones, exhibit anti-inflammatory activity via binding to the cytoplasmic corticosteroid receptor, which leads to inhibitions of HAT (histone acetyltransferase) and recruitment of HDAC2 (histone deacetylases 2) activity to downregulate inflammatory genes (102). Thus, corticosteroids have been widely used to control cytokine storms. Data from a limited-size trial showed that the early use of low or medium doses of methylprednisolone had a positive effect for patients with severe COVID-19 (103). A single-blind, randomized, controlled trial in Iran (trial identifier: IRCT202004046947N1) suggested that methylprednisolone pulse could be an efficient therapeutic agent for hospitalized severe COVID-19 patients at the pulmonary phase (104). Although there was no significant difference in mortality, patients receiving methylprednisolone treatment seemed to be with a faster improvement of oxygen saturation, decrease in CRP and IL-6 level, and less demand for invasive ventilation (104, 105). However, adverse effects (including serious infection and edema etc.) were also observed in several patients after the methylprednisolone treatment (103–105). In addition, there are heated debates as to whether corticosteroid therapy will delay viral clearance in COVID-19 (106, 107). Therefore, the pros and cons should be carefully weighed before using glucocorticoids in the treatment of COVID-19 patients. It is very important for clinicians to master the time and dose of corticosteroids for the treatment of severe patients, especially before the infection occurs. In addition, great caution should be exercised for patients who already have hypoxemia for various reasons or those who take glucocorticoids regularly due to other chronic diseases.

Blood Purification Therapy
It has been demonstrated that the blood purification system, such as plasma exchange, adsorption, perfusion, blood/plasma filtration, can remove inflammatory factors and then reduce tissue damage of hyper-activated inflammatory responses (108). Li et al. demonstrated that the artificial liver blood purification system could rapidly remove inflammatory mediators, block cytokine storms, favor the balance of fluid, electrolytes and acid-base, and thus improve treatment efficacy in critical illnesses (109, 110). Ma et al. reported that three COVID-19 patients who received blood purification therapy were tolerable and effective in limited experiences (111). Successful recovery of a severe patient was also presented in one case report (112). Yang’s group developed a blood purification protocol for patients with severe COVID-19 based on previous experience in SARS and MERS, including four major steps: (i) to assess whether patients with severe COVID-19 require blood purification; (ii) to prescribe a blood purification treatment for patients with COVID-19; (iii) to monitor and adjust parameters of blood purification; (iv) to evaluate the timing of discontinuation of blood purification (113). Last but not least, possible adverse effects in blood purification therapy (such as allergies, thrombocytosis, bleeding, air embolism etc.) should be timely identified and controlled to ensure safe and effective treatment (109–113).

Stem Cell Therapy
As an important member of the stem cell family, mesenchymal stem cells (MSCs) not only have potentials for self-renewal and multidirectional differentiation but also have strong anti-inflammatory and immune regulatory functions (114–117). In addition, MSCs inhibit abnormal activation of T lymphocyte cells and macrophages and induce their differentiation into regulatory T cells and anti-inflammatory macrophages (117). MSCs also obstruct the secretion of pro-inflammatory cytokines, thereby reducing the occurrence of cytokine storms (114, 115, 117, 118). Currently, over thirty clinical trials about intravenous administration of MSCs in COVID-19 patients have been officially registered (www.clinicaltrials.gov), but most of them are under the recruitment phase. Recently, Zhao et al. reported the results of seven severe and critically ill patients with COVID-19 receiving MSCs transplantation therapy, which showed improved prognosis and effective avoidance of cytokine storms with no obvious side effects (119). Furthermore, other stem cell therapies have been initiated in clinical trials, such as human menstrual blood-derived stem cells (ChiCTR2000031139) and embryonic stem cells (ChiCTR2000029606) and embryonic.
used to control cytokine storm have entered the stage of clinical trials for the treatment of COVID-19, the limited source and potential adverse effects have delayed widespread application in clinical treatment. Moreover, the best timing of anti-cytokine storm therapies remains to be explored, as well as novel therapeutic methods which are more effective and tolerated.

**AUTHOR CONTRIBUTIONS**

LT, YH, and HM: writing, original draft preparation. LT: table and figure preparation and editing. ZY, YH, and HM: review and editing. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was supported by funds from the Key Special Project of Ministry of Science and Technology of China (no. 2020YFC0845700), Scientific Research Projects of Chinese Academy of Engineering of China no. 2020-XY-70 (2020-KYGG-01-07), and Fundamental Research Funds for the Central Universities of China (no. 2020kyXGYJ029).

**REFERENCES**

1. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in humans: a descriptive study. *Chin Med J (Engl)* (2020) 133(9):1015–24. doi: 10.1097/cm9.0000000000000772
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *New Engl J Med* (2012) 367(19):1814–20. doi: 10.1056/NEJMoa1211721
3. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *New Engl J Med* (2003) 348(20):1967–76. doi: 10.1056/NEJMoa030747
4. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Potential for global spread of a novel coronavirus from China. *J Travel Med* (2020) 27(2):taaa011. doi: 10.1093/jtm/taaa011
5. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of potential for global spread of a novel coronavirus from China. *J Travel Med* (2020) 133(9):1015–20. doi: 10.1182/blood-2014-05-552729
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London Engl)* (2020) 395(10223):497–505. doi: 10.1016/S0140-6736(20)30185-9
7. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New Engl J Med* (2020) 382(18):1708–20. doi: 10.1056/NEJMoa2002032
8. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* (2017) 39(5):529–39. doi: 10.1007/s00281-017-0629-x
9. Shimabukuro-Vornhagen A, Gödel P, Sukhlewe M, Stemmler HJ, Schlösfer HA, Schlaak M, et al. Cytokine release syndrome. *J Immunother Cancer* (2018) 6(1):56. doi: 10.1186/s40425-018-0343-9
10. Ferrara JL, Abhayankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. *Transplant Proc* (1993) 25(1 Pt 2):1216–7.
11. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* (2014) 124(2):188–95. doi: 10.1182/blood-2014-05-552729
12. Fehr AR, Channappanavar R, Perlman S. Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. *Annu Rev Med* (2017) 68:387–99. doi: 10.1146/annurev-med-051215-031152
13. Krischuns T, Günf F, Henschel I, Binder M, Willemsen J, Schler S, et al. Phosphorylation of TRIM28 Enhances the Expression of IFN-β and Proinflammatory Cytokines During HPAIV Infection of Human Lung Epithelial Cells. *Front Immunol* (2018) 9:2229. doi: 10.3389/fimmu.2018.02229
14. Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. *Arthritis Rheumatol* (2017) 69(6):1135–43. doi: 10.1002/art.40071
15. Klinkhammer J, Schneff D, Ye L, Schwaderlapp M, Gad HH, Hartmann R, et al. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. *Elife* (2018) 7:e33354. doi: 10.7554/elif.e33354
16. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cell Mol Immunol* (2016) 13(1):3–10. doi: 10.1038/cmi.2015.74
17. Us D. Cytokine storm in avian influenza. *Microbiol Bul* (2008) 42(2):365–80.
18. Thomas M, Mani RS, Philip M, Adhikary R, Joshi S, Revadi SS, et al. Proinflammatory chemokines are major mediators of exacerbant immune response associated with Influenza A (H1N1) pdm09 virus infection. *J Med Virol* (2017) 89(8):1373–81. doi: 10.1002/jmv.24781
19. Wang CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan HHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol* (2004) 136(1):95–103. doi: 10.1111/j.1365-2249.2004.02413.x
20. Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. *Infect Immun* (2004) 72(8):4410–5. doi: 10.1128/iai.72.8.4410-4415.2004
21. Chien JY, Hsuhe PR, Cheng WC, Yu CJ, Yang PC. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. *Respir Med* (2006) 11(6):715–23. doi: 10.1111/j.1440-1843.2006.00942.x
22. Mahalavii WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BAJC. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine* (2018) 104:8–13. doi: 10.1016/j.jcyt.2018.01.025
23. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. *J Korean Med Sci* (2016) 31(11):1717–25. doi: 10.3346/jkms.2016.31.11.1717
24. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. *Semin Immunopathol* (2017) 39(5):517–28. doi: 10.1007/s00281-017-0639-8
25. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. *Microbiol Mol Biol Rev MMBR* (2012) 76(1):16–32. doi: 10.1128/MMBR.00515-11
26. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *Lancet Infect Dis* (2012) 12(9):687–95. doi: 10.1016/s1473-3099(12)70121-4
27. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* (2020) 130(5):2620–9. doi: 10.1172/jci137244
28. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* (2020) 46(5):846–8. doi: 10.1007/s00134-020-05999-x
29. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. *J Exp Med* (2020) 217(216):e20200678. doi: 10.1084/jem.20200678
71. Defferées SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open (2020) 3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136

72. Li Y, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epidemic of 2019- novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect (2020) 22(2):80–5. doi: 10.1016/j.micinf.2020.02.002

73. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol (2020) 92(5):491–4. doi: 10.1002/jmv.25709

74. Cremona ES, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv (2020) 2020.33.202004588. doi: 10.1101/2020.03.30.2004588.

75. Ulhaz ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Maladies Infectieuses (2020) 50(4):382–3. doi: 10.1016/j.jmed.infect.2020.04.002

76. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Adoptive Cell Therapy with Tocilizumab for the Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv (2020) 117(20):10970–5. doi: 10.1038/s41596-020-04117-6

77. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv (2020) 117(20):10970–5. doi: 10.1038/s41596-020-04117-6

78. Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6 (2020) 92(5):491–4. doi: 10.1002/jmv.25709

79. Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6 blockade for severe COVID-19. MedRxiv (2020) 2020.04.20.2006186. doi: 10.1101/2020.04.20.2006186

80. Tonieti P, Piva S, Cattalin M, Garlfe E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev (2020) 19(7):102568. doi: 10.1016/j.autrev.2020.102568

81. Malige J, Schoones JW, Pijs BG. Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis (2020) ciaa1445. doi: 10.1093/cid/ciaa1445

82. Masia M, Fernández-González M, Padilla S, Ortega P, García JA, Aguilló V, et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. EBioMedicine (2020) 60:102999. doi: 10.1016/j.ebiom.2020.102999

83. Caballero Bermejo AF, Ruiz-Antora SAC, Ruiz-Antora F. The epidemic of 2019- novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect (2020) 22(2):80–5. doi: 10.1016/j.micinf.2020.02.002

84. Garcia-Vicuña R, Abad-Santos F, González-Alvaro I, Ramos-Lima F, Sanz JS. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard care (SARCOV): A structured summary of a study protocol for a randomised controlled trial. Trials (2020) 21(1):794. doi: 10.1186/s13063-020-04633-3

85. García-Vicuña R, Abad-Santos F, González-Alvaro I, Ramos-Lima F, Sanz JS. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard care (SARCOV): A structured summary of a study protocol for a randomised controlled trial. Trials (2020) 21(1):772. doi: 10.1186/s13063-020-04588-5

86. Montesarchio V, Parrella R, Iommi C, Bianco A, Manzillo E, Fraganza F, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer (2020) 8(2):e001089. doi: 10.11136/jitc-2020-001089

87. Vaidya G, Czer LSC, Kobashigawa J, Kittleson M, Patel J, Chang D, et al. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplant Prog (2020) 52(3):e271–4. doi: 10.1016/j.transpros.2020.06.003

88. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatol (Oxford) (2015) 54(12):2134–44. doi: 10.1093/rheumatology/kev269

89. Ben-Zvi I, Kukuy O, Giat E, Praz E, Feld O, Kvitivy S, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol (2017) 69(4):854–62. doi: 10.1002/art.39995

90. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Results of a Randomized Controlled Trial. Blood (2020) 135(24):2757–81. doi: 10.1182/blood.2019-002142

91. Feldmann M, Maini RN, Wyburd VN, Wolgemuth W, Wardlaw M, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet (2020) 395(10234):1407–9. doi: 10.1016/S0140-6736(20)30888-8

92. Qin C, Zhou J, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis (2020) 71(15):762–8. doi: 10.1093/cid/ciaa248

93. Blaszczak A, Trinidad JCL, Cartron AM. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations. J Am Acad Dermatol (2020) 83(1):e31. doi: 10.1016/j.jaad.2020.04.030

94. Acebes P, Vajkoczy P, Monga S, Kolb M, Kast K, et al. Successful Treatment of Severe COVID-19 Pneumonia: A Case Report with Concurrent Tocilizumab Treatment. Expert Rev Anti Infect Ther (2020) 18(9):1119–22. doi: 10.1080/14787274.2020.1799095

95. Maschaldl S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hyperinflammatory syndrome in mice. Blood (2016) 128(1):60–71. doi: 10.1182/blood-2016-02-700013

96. Torresen J, Larsen CG, Christensen BM, Kjaergaard KM, Hammerslev R, et al. IL-6 and Mortality in COVID-19 Patients: A Retrospective Study. JAMA Netw Open (2020) 3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136

97. Tang et al. Cytokine Storm in COVID-19
106. Ji J, Zhang J, Shao Z, Xie Q, Zhong L, Liu Z. Glucocorticoid therapy does not delay viral clearance in COVID-19 patients. *Crit Care* (2020) 24(1):565. doi: 10.1186/s13054-020-03287-6

107. Huang R, Zhu C, Jian W, Xue L, Li C, Yan X, et al. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients. *Eur J Pharmacol* (2020) 889:173556. doi: 10.1016/j.ejphar.2020.173556

108. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J Infect* (2020) 80(6):607–13. doi: 10.1016/j.jinf.2020.03.037

109. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. *Zhejiang Da Xue Xue Bao* (2020) 49(4):40. doi: 10.3785/j.issn.1008-9292.2020.02.02

110. Zhang Y, Yu L, Tang L, Zhu M, Jin Y, Wang Z, et al. A Promising Anti-Cytokine Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System. *Eng (Beijing)* (2020). doi: 10.1016/j.jeng.2020.03.006

111. Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. *Clin Immunol* (2020) 214:108408. doi: 10.1016/j.clim.2020.108408

112. Wang Q, Hu Z. Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification. *Int J Infect Dis* (2020) 96:618–20. doi: 10.1016/j.ijid.2020.05.065

113. Yang XH, Sun RH, Zhao MY, Chen Ez, Liu J, Wang HL, et al. Expert recommendations on blood purification treatment protocol for patients with severe COVID-19: Recommendation and consensus. *Chronic Dis Transl Med* (2020) 6(2):106–14. doi: 10.1016/j.cdtm.2020.04.002

114. Li N, Hua J. Interactions between mesenchymal stem cells and the immune system. *Cell Mol Life Sci* (2017) 74(13):2345–60. doi: 10.1007/s00018-017-2473-5

115. Galipeau J, Sensébé L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. *Cell Stem Cell* (2018) 22(6):824–33. doi: 10.1016/j.stem.2018.05.004

116. Atluri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. *Pain Physician* (2020) 23(2):E71–e83.

117. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. *Cell Transplant* (2010) 19(6):667–79. doi: 10.3727/096368910x508762

118. Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. *Ann N Y Acad Sci* (2015) 1351:114–26. doi: 10.1111/nyas.12815

119. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. *Aging Dis* (2020) 11(2):216–28. doi: 10.14336/ad.2020.0228

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Tang, Yin, Hu and Mei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.